An Alzheimer's Disease Research Study
Researchers at McLean Hospital are conducting a clinical research study for those with psychosis associated with Alzheimer’s disease.
Fast Facts
Ages 55-90 with Alzheimer's Disease
Psychotic Symptoms for At Least 2 Months
Compensation Provided
Conducted in Belmont, MA
Study Background
This study is being conducted to evaluate the safety and effectiveness of an investigational drug for treating psychosis in individuals with Alzheimer’s disease.
Current treatment options for psychosis associated with Alzheimer’s disease include antipsychotics, which come with a black box warning (indicating serious safety risks) and significant side effects. Our research team is searching for safer treatment options.
Study Background
This study is being conducted to evaluate the safety and effectiveness of an investigational drug for treating psychosis in individuals with Alzheimer’s disease.
Current treatment options for psychosis associated with Alzheimer’s disease include antipsychotics, which come with a black box warning (indicating serious safety risks) and significant side effects. Our research team is searching for safer treatment options.
Additional Information
This study will test how effective and safe an investigational drug may be in people experiencing psychosis related to Alzheimer’s disease. Our eventual goal is to establish safer treatment options to improve the lives of individuals with AD as well as their caregivers.
You or someone you are caring for may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 55-90
- Diagnosed with Alzheimer’s disease
- History of psychotic symptoms associated with Alzheimer’s Disease for at least 2 months
- Have a caregiver who can accompany you to study visits
Exclusion Criteria:
- Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
- Psychotic symptoms can be attributed to another disorder besides Alzheimer’s disease
This is a 14-week in-person clinical trial involving an investigational drug.
Participants will go through a screening period to be determined eligible. During this screening period, participants will come in-person for a study visit.
If eligible for the study, participants will be asked to take either the study drug or a placebo (an inactive substitute) for 14 weeks. Over these 14 weeks, there are 8 in-person visits and 3 phone/virtual visits.
During these visits, participants will be asked to:
- Do mental health and cognitive assessments
- Give medical history
- Receive a physical exam, ECG, blood draws, and/or urinalysis
Participants will be compensated up to $750 for completing the entire study. Additional compensation for travel reimbursement and meals is available for each visit.
There is no cost to participate in our research study.
